| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Revenue | $8.23B | +7.2% |
| Cost of Revenue | $2.49B | +13.8% |
| R&D Expense | $458.5M | +4.8% |
| SG&A Expense | $3.26B | +11.2% |
| Operating Income | $1.10B | -14.6% |
| Pre-tax Income | $830.8M | -19.9% |
| Income Tax | $125.7M | -4.3% |
| Net Income | $705.1M | -22.0% |
| EPS (Basic) | $3.56 |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $591.9M | +12.6% |
| Accounts Receivable | $1.70B | +15.1% |
| Inventory | $2.29B | +2.3% |
| Current Assets | $5.12B | +9.6% |
| Total Assets | $23.09B | +8.1% |
| Current Liabilities | $2.58B | +5.4% |
| Long-term Debt | $1.00B | -81.3% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | $1.70B | +13.2% |
| Capital Expenditures | $224.5M | +10.2% |
| Investing Cash Flow | -$1.98B | -122.5% |
| Financing Cash Flow | $326.0M | +167.3% |
| Free Cash Flow | $1.47B | +13.7% |
| -20.0% |
| EPS (Diluted) | $3.55 | -19.9% |
| Total Liabilities |
| $10.39B |
| +16.8% |
| Stockholders' Equity | $12.70B | +1.8% |